DR ANNE-MARIE MES-MASSON, PH.D

Full professor, University of Montréal;
Dept. Medicine, Faculty of Medicine;
Institut du cancer de Montréal, CRCHUM, University of Montréal.
 
Key words: ovarian and prostate cancers, biobank, molecular and cell biology, ovarian cancer models, tissue microarray, prognostic and predictive biomarkers, new therapeutics, microfluidics

 

Contact :

anne-marie.mes-masson@umontreal.ca

Office: 514-890-8000 x.25496

Laboratory: 514-890-8000 x.25491

1979  B.Sc. – University of Ottawa – Cellular Biology

1984  Ph.D. - McGill University - Virology/Molecular Biology

1986  Post-doc - University of California, Los Angeles - Molecular Biology

1990-1993  FRQS Chercheur boursier: Junior 1          

1994-1995  FRQS Chercheur boursier: Junior 2          

1995-1999  FRQS Chercheur boursier: Senior          

1999-2004  FRQS Chercheur boursier: National 

  • 2015-2019 (PI) Strategic grant, Quebec Breast Cancer Foundation
    “Quebec breast cancer foundation tissue microarray consortium for biomarker evaluation”

  • 2011-2018 (PI) Team grant, Terry Fox Research Institute
    “A pan-Canadian platform for the development of biomarker-driven subtype specific management of ovarian cancer (Phase II)”

  • 2011-2018 (PI) Network grant, Fonds de recherche du Quebec-Santé
    “Réseau de recherche sur le cancer”

  • 2015-2017 (PI) Operating grant, Cancer Research Society
    “Ovarian tumors on-chip: quantitative tools to predict chemo response using patient-specific proliferation assays”

  • 2015-2017 (PI) Operating grant, Cancer Research Society
    “PARP inhibitor response in epithelial ovarian cancer: theranostic biomarkers and combination therapies”

  • 2015-2016 (PI) Operating grant, Canadian Institutes of Health Research
    “Bridging discovery to clinic: from biomarkers to therapeutic developments in ovarian cancer”

  • 2014-2016 (PI) Operating grant, Canadian Cancer Society Research Institute
    “Microfluidic based empirical testing versus predictive biomarkers to stratify cancer care in ovarian cancer patients”

  • 2013-2016 (co-PI) Team grants, Movember GAP1
    “Unique TMAs project” and “Tissue biomarker project”

  • 2012-2016 (co-PI) Team grant, Terry Fox Research Institute
    “Canadian Prostate Cancer Biomarker Network - Phase II)”

 

Awards and prizes

2014  Prix d’excellence de carrière - Centre de recherche du CHUM

2013  Karen Campbell Award for Research Excellence - Ovarian Cancer Canada

2010  Chercheure Ph.D. de l'année - Département de médecine, Université de Montréal 

Molecular characeteristics of ovarian and prostate cancer

Dr. Mes-Masson has a longstanding interest in fundamental, translational and clinical research in ovarian and prostate cancers. Dr. Mes-Masson has invested considerable efforts into the establishement of extensive ovarian and prostate tissue repositories (including fresh frozen specimens from normal, benign and tumor tissues, and paraffin embedded samples). She has developed several ovarian cancer models, including primary cultures from clinical material, spontaneously immortalized unique ovarian cancer cell lines as well as 3D spheroids and mouse xenografts that have been used in research studies. Dr. Mes-Masson’s research interests focus on the molecular features of ovarian and prostate cancers as an approach towards understanding the etiology and biology of these cancers. Prognostic and predictive biomarkers are studied at the gene and protein levels using the tissue repository and the derived cell line models. Using these resources Dr. Mes-Masson has identified genes modulated during the course of disease initiation and progression and have characterized biological parameters that are affected by the modulation of candidates using both in vitro and in vivo assays. Dr. Mes-Masson’s research is also directed towards the development of novel therapeutic strategies for ovarian and prostate cancer treatments.  Moreover, she has recently incorporated the microfluidics technology for empirical drug testing using 3D spheroids as well as ex-vivo micro-dissected tumors from mouse xenografts and patient samples.

 

Current projets (techniques used):

  1. Prognostic and predictive biomarker discovery using gene microarray, SNP array and deep sequencing. Biomarkers are validated at the protein level by immunohistochemistry or immunofluorescence on a tissue microarray platform.   

  2. Development of new treatment strategies for high-grade serous epithelial ovarian cancer (EOC) using poly-ADP ribose polymerase inhibitors in combination with other therapeutic drugs.

  3. Investigate the pivotal role of small GTPAse Ran at mitosis in cancer cells and establish the link between aneuploidy and Ran dependency using our unique panel of EOC cell lines, exhibiting complex karyotypes and diverse chemo-responses.

  4. Development of  new small molecules that inhibit Ran and evaluate their therapeutic value taking advantage of our in vitro and in vivo EOC models.

  5. Analysis of chemotherapy response using ex-vivo microdissected tumors (MDTs) cultured on microfluidics devices. MDTs are derived from xenograft models of our cell lines or from ovarian and prostate cancer patients. The value of this empirical testing is compared to predictive biomarkers on tissue microarrays.

  6. Effect of androgen receptor stimulation/inhibition and IKKe expression on cell motility, proliferation and survival (cell death, senescence, cell cycle arrest) of hormone-sensitive and castrate-resistant prostate cancer cells.

 

Associated websites:

  1. CRCHUM webpage
  2. Programme de biologie moléculaire de l’Université de Montréal
  3. Réseau de recherche en cancer

Plateforms: 

  1. Molecular Pathology

 

 

 Post-docs

  1. Abdul Lateef (lateefjh@gmail.com)
  2. Zied Boudhraa (boudhra.zied@gmail.com)
  3. Shuofei Cheng (shuofei.cheng@gmail.com)
  4. Laudine Communal (laudine.communal@gmail.com)
  5. Amine Lounis (lounis.amine@hotmail.com)

Former (past 5 years)

  1. Guergana Tchakarska
  2. Mohana Marimthu
  3. Michael Quinn
  4. Das Tamal
  5. Isabelle Letourneau
  6. Valérie Forrest
  7. Mustapha Benaissa

PhD Students

  1. Sylvie Clairefond (clairefond.sylvie@gmail.com)
  2. Hubert Fleury (fleury.hu@gmail.com)
  3. Maxime Cahuzac (maxime.cahuzac@umontreal.ca)

Former (past 5 years)

  1. Ingrid Labouba
  2. Philippe Gannon
  3. Magdelena Zietarska
  4. Julie Lafontaine
  5. Hervé Koumakpayi

MSc Students

  1. Alexandre Sauriol (alexandre.sauriol.1@umontreal.ca)
  2. Kayla Simeone (kayla.simeone@umontreal.ca)
  3. Sara Al Rubaish (sararubaish@hotmail.com)

Former (past 5 years)

  1. Khalid Akkour
  2. Marc Olivier Bienz
  3. Mélina Astolfi
  4. Jacinthe Roussy
  5. Rayane El Masri
  6. Lu-Lin Wang
  7. Véronique Barres
  8. Julie Desgagnés
  9. Karine Normandin
  10. Vincent Fradet

Research Associates

  1. Euridice Carmona (euricarmona@gmail.com)
  2. Cécile Le Page (cecilelepage@yahoo.ca)
  3. Benjamin Péant (peantb@yahoo.fr)
  4. Véronique Ouellet (ouelletv@gmail.com )

Senior Research Assistants

  1. Estelle Schmitt (estellem.schmitt@gmail.com)
  2. Kossay Zaoui (kossay.zaoui@mail.mcgill.ca)

Research Assistants

  1. Alexandria Aubourg (alexandria.aubourg.chum@ssss.gouv.ca)
  2. Chantale Auger (chantaleauger12@yahoo.com)
  3. Véronique Barrès (veronique.barres@gmail.com)
  4. Monique Bernard (monique.bernard@umontreal.ca)
  5. Renée Bernatchez (renee.bernatchez.chum@ssss.gouv.qc.ca)
  6. Christine Caron (caron_christine25@hotmail.com)
  7. Geneviève Cormier (genevievecormier@gmail.com)
  8. Manon de Ladurantaye (manon.deladurantaye.chum@ssss.gouv.qc.ca)
  9. Nathalie Delvoye (nathaliedelvoye@yahoo.ca)
  10. Gabriela Fragoso (fragosogabriela@yahoo.com)
  11. Doris Jiofack (risdoj@yahoo.fr)
  12. Jennifer Kendall-Dupont (jen.kendalldupont@gmail.com)
  13. Kim Leclerc-Desaulniers (kim.leclerc-desaulniers.chum@ssss.gouv.qc.ca)
  14. Liliane Meunier (liliane.meunier@gmail.com)
  15. Adriana Orimoto (adriorimoto@gmail.com)
  16. Lise Portelance (liseportelance@yahoo.ca)
  17. Claudia Syed (claudia.syed@gmail.com)
  18. Teodora Yaneva (teoyan@gmail.com)

Research Staff

  1. Ashley Harrison (ashley_s_harrison@hotmail.com)
  2. Zoey Masson (zoey.masson@gmail.com)

Admnistrative Assistants

  1. Louise Champoux (louise.champoux3@sympatico.ca)
  2. Mélanie Morin (melanie.morin.chum@ssss.gouv.qc.ca)

Scientific Writer

Jacqueline Chung (jwachung@gmail.com)

Bioinformatician

Nicolas Luc (nicol.luc@gmail.com)

  1.  Kobel, M., et al., An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. Int J Gynecol Pathol, 2016.
  2. Astolfi, M., et al., Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy. Lab Chip, 2016. 16(2): p. 312-25.
  3. Koti, M., et al., A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer, 2015. 112(7): p. 1215-22.
  4. Fleury, H., et al., Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes Cancer, 2015. 6(9-10): p. 378-98.
  5. Marques, M., et al., Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors. BMC Med, 2015. 13: p. 217.
  6. Labouba, I., et al., Potential Cross-Talk between Alternative and Classical NF-kappaB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay. PLoS One, 2015. 10(7): p. e0131024.
  7. Chene, G., et al., The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis. Int J Gynaecol Obstet, 2015. 130(1): p. 27-30.
  8. Le Page, C., et al., Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. Biopreserv Biobank, 2013. 11(2): p. 83-93.
  9. Deschenes-Simard, X., et al., Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev, 2013. 27(8): p. 900-15.
  10. Wiegand, K.C., et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med, 2010. 363(16): p. 1532-43.